Dipyridamole (Persantine)

2611  relevant articles (165 outcomes, 494 trials/studies) found for this Drug

Persantine; Miosen; Antistenocardin; Apo-Dipyridamole; Apotex Brand of Dipyridamole; Ashbourne Brand of Dipyridamole; Belmac Brand of Dipyridamole; Berlin-Chemie Brand of Dipyridamole; Boehringer Ingelheim Brand of Dipyridamole; Cerebrovase; Cléridium; Curantil; Curantyl; Dipyramidole; IPRAD Brand of Dipyridamole; Kurantil; Novo-Dipiradol; Novopharm Brand of Dipyridamole; Persantin; Berlin Chemie Brand of Dipyridamole; Ethanol, 2,2',2'',2'''-((4,8-di-1-piperidinylpyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilo)tetrakis-

Relationship Network

Drug Context: Research Results

Experts

1.	Picano, Eugenio: 10 articles (01/2008 - 04/2002)
2.	Picano, E: 7 articles (12/2003 - 01/2000)
3.	De Schryver, E L L M: 5 articles (01/2007 - 01/2003)
4.	Diener, Hans-Christoph: 4 articles (09/2008 - 01/2005)
5.	van Gijn, J: 4 articles (01/2007 - 01/2003)
6.	Algra, A: 4 articles (01/2007 - 01/2003)
7.	Hiraki, Tatsuro: 3 articles (01/2008 - 06/2005)
8.	Zhao, Lian: 3 articles (01/2008 - 03/2005)
9.	Imaizumi, Tsutomu: 3 articles (01/2008 - 06/2005)
10.	Matsumoto, Manabu: 3 articles (01/2008 - 06/2005)

Related Diseases

1.	Stroke (Strokes) 09/15/1998 - "The sustained release dipyridamole produced a significant risk reduction of 16% for stroke, 15% for stroke and/or death but no significant reduction of mortality" 07/01/2008 - "Recent studies suggest that dipyridamole (DP) may exert stroke protective effects beyond platelet inhibition" 07/01/2008 - "OBJECTIVE: The purpose of this review was to discuss results from clinical trials that have compared the efficacy of ASA monotherapy versus ASA + extendedrelease dipyridamole in secondary stroke prevention" 07/01/2008 - "CONCLUSION: Based on the results from these 2 large, randomized trials, ASA + dipyridamole was more effective than ASA monotherapy as first-line therapy for secondary stroke prevention in these patients with a history of minor stroke or TIA of noncardioembolic etiology." 06/01/2008 - "Two large clinical trials have established the superiority of the combination of ASA and extended-release dipyridamole (ASA/ERDP) over ASA alone in patients with recent noncardioembolic ischemic stroke or TIA" Get all the results and reference details, order at left...
2.	Myocardial Infarction 12/01/1993 - "Dipyridamole echocardiography was well tolerated by elderly patients and proved to be very effective in prognostic stratification early after uncomplicated acute myocardial infarction, even when only survival was considered." 09/01/1997 - "CONCLUSIONS: Echocardiographic imaging during dipyridamole infusion is superior to sestamibi scintigraphy for predicting events after uncomplicated myocardial infarction." 03/01/1990 - "We have not found dipyridamole to be effective in the dog with coronary artery constriction and find no substantial evidence that it is effective in preventing myocardial infarction in man" 07/01/1998 - "The aim of our study was to compare the prognostic information obtained early after an acute uncomplicated myocardial infarction of high dose dipyridamole coupled with echocardiography (stress echo) or maximal symptom-limited exercise testing" 09/01/1997 - "The aim of our study was to compare the prognostic information obtained early after an acute uncomplicated myocardial infarction through high-dose dipyridamole coupled with echocardiography or scintigraphy via Tc 99m sestamibi SPECT imaging" Get all the results and reference details, order at left...
3.	Myocardial Ischemia (Ischemic Heart Diseases) 03/01/1991 - "Thus, evaluation of early washout ratios (WR-25) after dipyridamole injection is a valuable method to increase sensitivity in assessing regional myocardial perfusion abnormality and is helpful in detection of ischemic heart disease, even with multivessel disease." 08/01/2001 - "Dipyridamole nuclear myocardial perfusion test is a safe and effective alternative to exercise nuclear perfusion testing for detecting myocardial ischemia" 01/01/1996 - "In response to dipyridamole introduction improved myocardial perfusion was registered in 4 out of 6 patients, 1 patient showed signs of transient myocardial ischemia, 1 patient had stable defects of myocardial blood supply" 07/01/2002 - "Study aim was the prospective assessment of the impact of dipyridamole-induced myocardial ischemia on the signal-averaged ECG" 06/15/1994 - "Accordingly, the purpose of this study was to determine if reversible TI-201 defects in response to dipyridamole infusion are reflective of myocardial ischemia or secondary to regional differences in flow reserve" Get all the results and reference details, order at left...
4.	Coronary Artery Disease (Coronary Atherosclerosis) 10/01/1995 - "In patients with chronic coronary artery disease and a low incidence of cardiac events, dipyridamole echocardiography was effective in prognostic stratification, and positive low work load exercise ECG results were a reliable predictor of subsequent events" 07/15/1992 - "Intravenous dipyridamole planar thallium-201 imaging is a safe and effective test for detection and prognosis of coronary artery disease (CAD) in the general population" 03/01/1997 - "Simultaneous dipyridamole/maximal subjective exercise with 99mTc-MIBI SPECT: improved diagnostic yield in coronary artery disease." 02/01/1992 - "To evaluate the efficacy of stress technetium-99m MMI (N-2-methoxy-2-methyl propyl isonitrile) myocardial perfusion scintigraphy (Tc-99m MMI) using intravenous dipyridamole for detection of coronary artery disease (CAD), we collected 66 cases (53 men, 13 women, aged 40-79 years old) between Sept" 02/01/1988 - "Thus, dipyridamole cardiac imaging is helpful in the diagnosis of coronary artery disease and in risk stratification." Get all the results and reference details, order at left...
5.	Ischemia 08/01/1989 - "The increase in rate-pressure product (RPP = mm Hg x beats/min x 100) measured during the exercise stress test in the patients in group I was significantly greater than that determined during dipyridamole-induced ischemia (204 +/- 41 versus 145 +/- 33, p less than 0.01)" 06/01/1983 - "Rapid atrial pacing performed before and at 60, 90, and 120 minutes after dipyridamole failed to demonstrate any significant reduction in pacing threshold or evidence of increased ischemia after dipyridamole" 05/01/2004 - "STUDY DESIGN: Dipyridamole (DYP) was given by continuous intravenous infusion for 1 hour before ischemia at a dose of 0.25 mg/kg (high-DYP, n = 6), 0.1 mg/kg (medium-DYP, n = 6), or 0.05 mg/kg (low-DYP, n = 6)" 09/15/1993 - "This study evaluates dipyridamole stress echocardiography in silent ischemia" 09/01/1992 - "Dipyridamole given before the 30-minute ischemia, without preconditioning, did not reduce %IS/AR (55.3 +/- 5.2%, n = 7), and a previous study from this laboratory had demonstrated that the present dose of 8-PT alone did not modify IS in the rabbit" Get all the results and reference details, order at left...
378 Diseases and 2611 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Aspirin (Acetylsalicylic Acid)
2.	clopidogrel (Plavix)
3.	Platelet Aggregation Inhibitors (Antiplatelet Drugs)
4.	Thallium
5.	Ticlopidine (Ticlid)
6.	Adenosine
7.	Dobutamine
8.	Prednisolone (Predate)
9.	Dipyridamole (Persantine)
10.	Warfarin (Coumadin)
645 Drugs and Important Bio-Agents and 1635 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
3.	Plasma Exchange
4.	Prostheses and Implants (Prosthesis)
5.	Angioplasty (Angioplasties)
68 Therapies and Procedures and 228 more articles analyzed in the Research Interface, order at left...